Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- PMID: 29680197
- DOI: 10.1016/j.bcmd.2018.04.001
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Comment on
-
Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.Blood Cells Mol Dis. 2018 Feb;68:14-16. doi: 10.1016/j.bcmd.2017.09.003. Epub 2017 Sep 14. Blood Cells Mol Dis. 2018. PMID: 28935503 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical